MENU
Advertisement
Show Filters
Refine by Content Type
Refine by Year
Sort By:
Choose Sites to Search:
Radial Compression Devices Used After Cardiovascular Interventions
Discussing the design and function of radial artery compression technologies used for a safe closure of radial access after percutaneous cardiovascular intervention.
By Francesco Costa, MD, PhD, FESC, and Renato Scalise, MD
Contemporary Catheter-Based Structural Heart and Vascular Access Closure Options
By Rahul Sharma, MD, FACP, FACC, FSCAI, and Nicolas M. Van Mieghem, MD, PhD, FACC, FESC
Early Clinical Results Presented for Reva's ReZolve2 Bioresorbable Scaffold
October 28, 2013—Reva Medical, Inc. (San Diego, CA) announced that initial results from the clinical investigation of patients treated with the company's ReZolve2 sirolimus-eluting bioresorbable coronary scaffold were presented at the TCT 2013: Transcatheter Cardiovascular Therapeutics conference in San Francisco, California.
Acute and Chronic Antithrombotic Therapy in STEMI Patients Undergoing Primary PCI
A review of the anticoagulant and antiplatelet agents currently available for the treatment of STEMI patients undergoing PPCI.
By Dominick J. Angiolillo, MD, PhD, and Francesco Franchi, MD
Single-Center FORZA Trial Compares FFR and OCT Guidance for PCI
September 29, 2019—Findings from the FORZA trial were presented by Francesco Burzotta, MD, in a late-breaking trials session at TCT 2019, the 31st annual Transcatheter Cardiovascular Therapeutics scientific symposium held September 25–29 in San Francisco, California.
Feasibility Study Evaluates 4Tech's TriCinch Transcatheter Tricuspid Valve Repair
June 20, 2016—4Tech Inc. announced that the company’s transcatheter TriCinch device for repair of the tricuspid heart valve has been used to successfully treat patients with tricuspid regurgitation in an ongoing feasibility study that is being conducted at San Raffaele Hospital in Milan, Italy, and at other sites in Italy and Europe.
Mitral Technology & Lesion Assessment
By Ted E. Feldman, MD, MSCAI, FACC, FESC
Abbott Vascular Receives FDA Approval for Xience Prime DES
November 1, 2011—Abbott Vascular (Santa Clara, CA) announced that it has received US Food and Drug Administration (FDA) approval for the next-generation Xience Prime everolimus-eluting coronary stent system for the treatment of coronary artery disease.
The DES Landscape in 2011
Future directions in drug-eluting stent design.
By Jeffrey S. Kunz, MD, and Mark A. Turco, MD, FACC, FSCAI
Cost and Quality-of-Life PLATFORM Data Support FFRCT
October 13, 2015—Cost and quality-of-life outcomes from the PLATFORM trial were reported at TCT 2015, the 27th annual Transcatheter Cardiovascular Therapeutics scientific symposium of the Cardiovascular Research Foundation being held October 11–15, in San Francisco, California.
CSI San Francisco Conference Offers Fellows Scholarship Program
September 16, 2019—CSI San Francisco, a branch of the CSI Frankfurt conference, is offering a fellows scholarship program to support attendance at this year's conference to be held November 1–2 at the Grand Hyatt San Francisco in Union Square, San Francisco, California.
SPIRIT IV Results Published, Cost-Effectiveness Analysis Presented
May 5, 2010—Abbott Vascular (Santa Clara, CA) announced that Gregg W. Stone, MD, et al have published findings from the SPIRIT IV trial in the New England Journal of Medicine (2010;362:1663–1674). Abbott Vascular also announced that David Cohen, MD, presented findings from a retrospective cost-effectiveness analysis of SPIRIT IV data on March 13 at the Cardiovascular Research Foundation's Optimizing PCI Outcomes symposium in Atlanta.
COAPT Economic Analysis Demonstrates Cost-Effectiveness of TMVR With MitraClip
September 29, 2019—The Cardiovascular Research Foundation (CRF) announced that results from a new economic analysis of the COAPT trial data were presented by Suzanne J. Baron, MD, at TCT 2019, the 31st annual Transcatheter Cardiovascular Therapeutics scientific symposium, which is sponsored by CRF and held September 25–29 in San Francisco, California. The results were published simultaneously by Dr. Baron et al online in Circulation.
SPIRIT IV Safety and Efficacy Results Published and Cost-Effectiveness Analysis Presented
FDA Clears AliveCor's Mobile Heart Monitor for iPhone
December 3, 2012—AliveCor, Inc. (San Francisco, CA) announced that it has received 510(k) clearance from the US Food and Drug Administration, as well as CE Mark approval, for its mobile heart monitor.
Quality-of-Life and Economic Analyses of Edwards Sapien Valve in High-Risk Patients Presented at TCT
November 10, 2011—Edwards Lifesciences (Irvine, CA) announced data on the quality-of-life (QOL) impact and cost effectiveness of transcatheter aortic valve replacement (TAVR) in patients who are at high risk for surgery.
Targeting Aortic Stenosis Care
Insights from the Target: Aortic Stenosis initiative on best practices and barriers across the aortic stenosis care continuum.
By Mohammad Forouzannia, MD; Yousif Ahmad, MD; and Sammy Elmariah, MD, MPH
Presentations Support Accumetrics' VerifyNow System for Platelet Reactivity Testing
March 12, 2013—Accumetrics, Inc. (San Diego, CA), maker of the VerifyNow system, announced the presentation of a series of data that solidifies the clinical utility of platelet reactivity testing.
SAFE-PCI Examines Radial Artery Access in Women
October 29, 2013—The Cardiovascular Research Foundation (CRF) announced that findings from the SAFE-PCI for Women clinical trial suggest that an initial strategy of using radial artery access for cardiac catheterization or percutaneous coronary intervention (PCI) in women has potential for reducing bleeding complications.
